Product Description: Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167.